307 related articles for article (PubMed ID: 30943832)
1. Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Johnson K; Oparil S; Davis BR; Tereshchenko LG
J Am Heart Assoc; 2019 Apr; 8(8):e011961. PubMed ID: 30943832
[TBL] [Abstract][Full Text] [Related]
2. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Davis BR; Kostis JB; Simpson LM; Black HR; Cushman WC; Einhorn PT; Farber MA; Ford CE; Levy D; Massie BM; Nawaz S;
Circulation; 2008 Nov; 118(22):2259-67. PubMed ID: 19001024
[TBL] [Abstract][Full Text] [Related]
3. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Davis BR; Piller LB; Cutler JA; Furberg C; Dunn K; Franklin S; Goff D; Leenen F; Mohiuddin S; Papademetriou V; Proschan M; Ellsworth A; Golden J; Colon P; Crow R;
Circulation; 2006 May; 113(18):2201-10. PubMed ID: 16651474
[TBL] [Abstract][Full Text] [Related]
4. Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study.
Bang CN; Soliman EZ; Simpson LM; Davis BR; Devereux RB; Okin PM;
Am J Hypertens; 2017 Sep; 30(9):914-922. PubMed ID: 28430947
[TBL] [Abstract][Full Text] [Related]
5. Worsening Kidney Function Is the Major Mechanism of Heart Failure in Hypertension: The ALLHAT Study.
Khayyat-Kholghi M; Oparil S; Davis BR; Tereshchenko LG
JACC Heart Fail; 2021 Feb; 9(2):100-111. PubMed ID: 33189627
[TBL] [Abstract][Full Text] [Related]
6. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.
Einhorn PT; Davis BR; Massie BM; Cushman WC; Piller LB; Simpson LM; Levy D; Nwachuku CE; Black HR;
Am Heart J; 2007 Jan; 153(1):42-53. PubMed ID: 17174636
[TBL] [Abstract][Full Text] [Related]
7. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
JAMA; 2000 Apr; 283(15):1967-75. PubMed ID: 10789664
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Wright JT; Harris-Haywood S; Pressel S; Barzilay J; Baimbridge C; Bareis CJ; Basile JN; Black HR; Dart R; Gupta AK; Hamilton BP; Einhorn PT; Haywood LJ; Jafri SZ; Louis GT; Whelton PK; Scott CL; Simmons DL; Stanford C; Davis BR
Arch Intern Med; 2008 Jan; 168(2):207-17. PubMed ID: 18227370
[TBL] [Abstract][Full Text] [Related]
9. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763
[TBL] [Abstract][Full Text] [Related]
10. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).
Soliman EZ; Ambrosius WT; Cushman WC; Zhang ZM; Bates JT; Neyra JA; Carson TY; Tamariz L; Ghazi L; Cho ME; Shapiro BP; He J; Fine LJ; Lewis CE;
Circulation; 2017 Aug; 136(5):440-450. PubMed ID: 28512184
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Dewland TA; Soliman EZ; Yamal JM; Davis BR; Alonso A; Albert CM; Simpson LM; Haywood LJ; Marcus GM
Circ Arrhythm Electrophysiol; 2017 Dec; 10(12):. PubMed ID: 29212812
[TBL] [Abstract][Full Text] [Related]
12. Electrocardiographic measures of left ventricular hypertrophy in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Ernst ME; Davis BR; Soliman EZ; Prineas RJ; Okin PM; Ghosh A; Cushman WC; Einhorn PT; Oparil S; Grimm RH;
J Am Soc Hypertens; 2016 Dec; 10(12):930-938.e9. PubMed ID: 27938852
[TBL] [Abstract][Full Text] [Related]
13. Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.
Oparil S; Davis BR; Cushman WC; Ford CE; Furberg CD; Habib GB; Haywood LJ; Margolis K; Probstfield JL; Whelton PK; Wright JT;
Hypertension; 2013 May; 61(5):977-86. PubMed ID: 23529173
[TBL] [Abstract][Full Text] [Related]
14. Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on Conduction System Disease.
Dewland TA; Soliman EZ; Davis BR; Magnani JW; Yamal JM; Piller LB; Haywood LJ; Alonso A; Albert CM; Marcus GM;
JAMA Intern Med; 2016 Aug; 176(8):1085-92. PubMed ID: 27367818
[TBL] [Abstract][Full Text] [Related]
15. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).
Cushman WC; Ford CE; Cutler JA; Margolis KL; Davis BR; Grimm RH; Black HR; Hamilton BP; Holland J; Nwachuku C; Papademetriou V; Probstfield J; Wright JT; Alderman MH; Weiss RJ; Piller L; Bettencourt J; Walsh SM;
J Clin Hypertens (Greenwich); 2002; 4(6):393-404. PubMed ID: 12461301
[TBL] [Abstract][Full Text] [Related]
16. Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT.
Bangalore S; Davis BR; Cushman WC; Pressel SL; Muntner PM; Calhoun DA; Kostis JB; Whelton PK; Probstfield JL; Rahman M; Black HR;
Am J Med; 2017 Apr; 130(4):439-448.e9. PubMed ID: 27984005
[TBL] [Abstract][Full Text] [Related]
17. Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.
Lynch AI; Boerwinkle E; Davis BR; Ford CE; Eckfeldt JH; Leiendecker-Foster C; Arnett DK
Pharmacogenet Genomics; 2009 Jun; 19(6):415-21. PubMed ID: 19352213
[TBL] [Abstract][Full Text] [Related]
18. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
Rahman M; Ford CE; Cutler JA; Davis BR; Piller LB; Whelton PK; Wright JT; Barzilay JI; Brown CD; Colon PJ; Fine LJ; Grimm RH; Gupta AK; Baimbridge C; Haywood LJ; Henriquez MA; Ilamaythi E; Oparil S; Preston R;
Clin J Am Soc Nephrol; 2012 Jun; 7(6):989-1002. PubMed ID: 22490878
[TBL] [Abstract][Full Text] [Related]
19. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial.
Davis BR; Cutler JA; Furberg CD; Wright JT; Farber MA; Felicetta JV; Stokes JD;
Ann Intern Med; 2002 Sep; 137(5 Part 1):313-20. PubMed ID: 12204014
[TBL] [Abstract][Full Text] [Related]
20. The ALLHAT Trial. Diuretics are still the preferred initial drugs for high blood pressure.
Vidt DG
Cleve Clin J Med; 2003 Mar; 70(3):263-9. PubMed ID: 12678218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
